Codexis, Inc.（CDXS）财务数据CDXSCodexis, Inc.

Codexis, Inc. (CDXS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Performance Enzymes, accounting for 93.9% of total sales, equivalent to $8.71M. Other significant revenue streams include Product Revenue and Research and development revenue. Understanding this composition is critical for investors evaluating how CDXS navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Codexis, Inc. maintains a gross margin of 76.45%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -75.29%, while the net margin is -80.49%. These profitability ratios, combined with a Return on Equity (ROE) of -69.36%, provide a clear picture of how effectively CDXS converts its operational activities into shareholder value.

In the context of the broader market, CDXS competes directly with industry leaders such as ACNT and AMTX. With a market capitalization of $186.16M, it holds a leading position in the sector. When comparing efficiency, CDXS's gross margin of 76.45% stands against ACNT's 21.62% and AMTX's 21.56%. Such benchmarking helps identify whether Codexis, Inc. is trading at a premium or discount relative to its financial performance.

Codexis reported a narrower net loss of $12 million for Q2 2026, with a revenue of $14.9 million, down from $15.3 million in Q1 2026. The gross margin remains strong at 76.45%, but the company continues to struggle with profitability, as evidenced by a negative net income and EPS of -0.13.